BONA
15.1.2024 08:05:25 CET | Business Wire | Press release
Bona, a global, sustainably driven company that supplies products for installing, renovating, maintaining, and restoring premium floors, is announcing the launch of its new lacquer, Bona Mega EVO™. This next generation lacquer offers a new state-of-the-art crosslinking technology that activates when applied. The unique, non-yellowing formula delivers faster curing with excellent resistance to scratches, wear, and chemicals. With VOC levels below 3%, the lacquer contributes to healthier working conditions with a lower impact on indoor air quality.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240114100435/en/
Announcing Bona Mega EVO™ a next generation lacquer that offers new state-of-the-art crosslinking technology that activates when applied. The unique, non-yellowing formula delivers faster curing with excellent resistance to scratches, wear, and chemicals. With VOC levels below 3%, Bona Mega EVO contributes to healthier working conditions with a lower impact on indoor air quality. (Photo: Business Wire)
Bona Mega EVO™ is the next evolution of Bona Mega, which was first introduced in 1996 and offered an industry-first oxygen crosslinking technology and, at the time, was considered a top choice among flooring contractors for use as a one-component topcoat for wood floors in environments requiring medium to light commercial wear resistance. Bona Mega EVO™ is the next generation that incorporates a completely new and significantly faster technology that is unique to Bona. The self crosslinking occurs entirely within the lacquer without the use of any external components, making it a next generation coating.
“When it comes to performance, Bona Mega EVO™ is an advancement in every way. With the new self crosslinking technology, we have merged the top features from Bona Mega and Bona Mega ONE to create an exceptional product. It stands out from the competition due to its consistently high level of performance. Bona Mega EVO™ is the next step for coating medium- to light-commercial areas and domestic wood floors,” said Thomas Hallberg, Director Product Management Professional EMEA/APAC, Bona AB
Bona Mega EVO’s new self crosslinking technology provides a topcoat that dries quickly, remains clear over time, offers excellent sanding ability, and has VOC levels below 3%. It has high filling abilities, low odour, and excellent scratch, wear, and chemical resistance. With Bona Mega EVO’s fast-drying and quick cure time, the floor can be in use more quickly when compared to other one-component lacquers. This also means that the next topcoat layer can be applied much sooner than with traditional polymer technology.
Bona Mega EVO™ guarantees a uniform colouring of the wood floor even without the use of a primer making it possible to use just one product during the whole process. It has a non-yellowing formula with minimal odour during the application process and dissipates rapidly afterwards.
With VOC levels below 3%, Bona Mega EVO™ fulfills the EMICODE® EC1PLUS certification. Bona continues its work to phase out PFAS, of which Bona Mega EVO is no exception, promoting a safer environment.
About Bona
Bona is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. The head office is in Malmö, Sweden, and the company is represented globally across 90 countries through 16 subsidiaries, 70 distributors, 4 production sites and over 600 employees. For more visit www.bona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240114100435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom